ArticleCancers2022

Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.

Kamal Pandey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.